恒瑞医药(01276.HK)：注射用醋酸亮丙瑞林微球获批开展临床试验

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of its injectable leuprolide acetate microspheres, indicating a significant step in its product development pipeline [1] Group 1 - The company’s subsidiary, Shanghai Heng Rui Medicine Co., Ltd., is set to initiate clinical trials for the new drug [1] - The approval marks a crucial milestone in the company's efforts to expand its product offerings in the pharmaceutical market [1]